👤 Liangrui Zhou

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
1335
Articles
847
Name variants
Also published as: Aiping Zhou, Aiwu Zhou, Alicia Y Zhou, An Zhou, Ang Zhou, Anna Y Zhou, Annan Zhou, Ao Zhou, Aojia Zhou, Aoshuang Zhou, Apei Zhou, Baiwan Zhou, Bao-Sen Zhou, Baohua Zhou, Baojuan Zhou, Baosen Zhou, Beixian Zhou, Beiyi Zhou, Bin Zhou, Bincheng Zhou, Bing Zhou, Bingbing Zhou, Binghai Zhou, Bingqian Zhou, Bingqing Zhou, Bingying Zhou, Binhua P Zhou, Binhua Zhou, Birong Zhou, Bo Zhou, Bo-Ya Zhou, Bo-Yang Zhou, Bubo Zhou, C Zhou, C-J Zhou, Can Zhou, Carl Zhou, Cefan Zhou, Chang Zhou, Chang-Yin Zhou, Changfan Zhou, Changhua Zhou, Changqi Zhou, Changrui Zhou, Changshuai Zhou, Changwen Zhou, Chao Zhou, Chen-Hui Zhou, Chen-Liang Zhou, Chenchen Zhou, Cheng Zhou, Chengji J Zhou, Chenhao Zhou, Chenkang Zhou, Chenqi Zhou, Chenxia Zhou, Chong Zhou, Chong-zhi Zhou, Chongwei Zhou, ChuHuan Zhou, Chuan-Min Zhou, Chuan-Wei Zhou, Chuan-Xiang Zhou, Chuan-chuan Zhou, Chuanen Zhou, Chuanman Zhou, Chuhao Zhou, Chun-Man Zhou, Chun-Ni Zhou, Chunlei Zhou, Chunlin Zhou, Chunni Zhou, Chunxian Zhou, Chunxiu Zhou, Chunyu Zhou, Chunzhuang Zhou, Chuyu Zhou, Cui Zhou, Cuiqi Zhou, Da Zhou, Daijun Zhou, Daizhan Zhou, Dan Zhou, Danmei Zhou, Danxia Zhou, Dao Zhou, David Zhou, Dawei Zhou, Daxin Zhou, Degang Zhou, Dejun Zhou, Dezheng Zhou, Dingan Zhou, Dingzi Zhou, Dong-Sheng Zhou, Dongdong Zhou, Donger Zhou, Dongfang Zhou, Donghai Zhou, Dongjie Zhou, Dongmei Zhou, Dongsheng Zhou, Duanfang Zhou, Duo-Qi Zhou, Duoqi Zhou, Enchen Zhou, Ershun Zhou, F Zhou, Fachen Zhou, Fan Zhou, Fanfan Zhou, Fang Zhou, Fangfang Zhou, Fangli Zhou, Fangting Zhou, Fei Zhou, Feixue Zhou, Feiye Zhou, Feng Zhou, Feng-Quan Zhou, Fenghua Zhou, Fengrui Zhou, Fengyun Zhou, Fenling Zhou, Fu-Ling Zhou, Fude Zhou, Fuling Zhou, Fusheng Zhou, Fuxiang Zhou, Fuyou Zhou, G Zhou, Gang Zhou, Grace Guoying Zhou, Guangji Zhou, Guangjun Zhou, Guangming Zhou, Guangqian Zhou, Guangzhou Zhou, Gui-Feng Zhou, Guifeng Zhou, Guiju Zhou, Guili Zhou, Guiting Zhou, Guo Zhou, Guo-Kun Zhou, Guohong Zhou, Guohua Zhou, Guoli Zhou, Guoyu Zhou, Guyue Zhou, H Zhou, Haibo Zhou, Haihong Zhou, Haihua Zhou, Haijing Zhou, Haimei Zhou, Hairui Zhou, Haixu Zhou, Haiyan Zhou, Haiyuan Zhou, Haiyue Zhou, Han Zhou, Hang Zhou, Hang-Yu Zhou, Hangfan Zhou, Hanshen Zhou, Hanxiao Zhou, Hao Zhou, Hao-Min Zhou, Haobo Zhou, Haonan Zhou, Haoxiong Zhou, Haoyuan Zhou, He Zhou, Helen Zhou, HengCui Zhou, Heying Zhou, Hong Zhou, Hong-Yu Zhou, Honghong Zhou, Hongji Zhou, Honglei Zhou, Hongli Zhou, Hongmei Zhou, Hongmin Zhou, Hongshan Zhou, Hongwei Zhou, Hongwen Zhou, Hongyan Zhou, Hou-De Zhou, Hu Zhou, Hua Ying Zhou, Hua Zhou, Hua-Bang Zhou, Huadong Zhou, Huaijun Zhou, Huamao Zhou, Huan Zhou, Huangao Zhou, Huanjin Zhou, Huanyu Zhou, Huaqiang Zhou, Hui Zhou, Hui-Fen Zhou, Huifang Zhou, Huifen Zhou, Huihui Zhou, Huimin Zhou, Huinian Zhou, Huiqiang Zhou, Huiwen Zhou, J Zhou, Jeff Xiwu Zhou, Ji Zhou, Ji-Chao Zhou, Ji-Ying Zhou, Jia Zhou, Jia-Guo Zhou, Jia-le Zhou, Jiahe Zhou, Jiahua Zhou, Jiajie Zhou, Jiale Zhou, Jiamei Zhou, Jian Zhou, Jian-Peng Zhou, JianJiang Zhou, Jianan Zhou, Jianfen Zhou, Jianfeng Zhou, Jiang-Ning Zhou, Jiangfei Zhou, Jianghao Zhou, Jianghong Zhou, Jianghui Zhou, Jianglin Zhou, Jiangqiao Zhou, Jianguo Zhou, Jianhua Zhou, Jianling Zhou, Jianmin Zhou, Jianqing Zhou, Jianshe Zhou, Jianwei Zhou, Jianying Zhou, Jianzhong Zhou, Jiaqi Zhou, Jiaru Zhou, Jiawang Zhou, Jiawei Zhou, Jiawen Zhou, Jiaxi Zhou, Jiaxiang Zhou, Jiaxin Zhou, Jiayan Zhou, Jiayi Zhou, Jiayin Zhou, Jie Zhou, Jiechao Zhou, Jiefu Zhou, Jieru Zhou, Jieyan Zhou, Jieyu Zhou, Jin Zhou, Jin-Ting Zhou, Jin-Yong Zhou, JinQiu Zhou, Jing Zhou, Jing-Wei Zhou, Jing-Xuan Zhou, Jingbo Zhou, Jingjie Zhou, Jingjing Zhou, Jingjun Zhou, Jingpei Zhou, Jingqi Zhou, Jingwen Zhou, Jingyi Zhou, Jingyu Zhou, Jingyuan Zhou, Jinting Zhou, Jinyi Zhou, Jiuyao Zhou, Jiyong Zhou, John Zhou, Ju Zhou, Juan Zhou, Juanjuan Zhou, Jue-Yu Zhou, Julian Q Zhou, Jun Zhou, Jun-Min Zhou, Jun-Ying Zhou, Jun-Yu Zhou, Jundong Zhou, Junfeng Zhou, Jungu Zhou, Junguo Zhou, Junhe Zhou, Junjie Zhou, Junjun Zhou, Junting Zhou, Junya Zhou, Junyu Zhou, Justin Zhou, Juying Zhou, Kaicheng Zhou, Kaixia Zhou, Kaixin Zhou, Kaiyu Zhou, Kan Zhou, Ke Zhou, Kecheng Zhou, Kefu Zhou, Kejin Zhou, Kexun Zhou, Lamei Zhou, Lan Zhou, Lang Zhou, Lanlan Zhou, Lanping Zhou, Lanqi Zhou, Laura Y Zhou, Le Zhou, Lei Zhou, Lei-Lei Zhou, Li Zhou, Li-Jun Zhou, Liang Zhou, Liangdong Zhou, Liangfu Zhou, Liangxue Zhou, Liangyu Zhou, Libin Zhou, Libing Zhou, Libo Zhou, Liche Zhou, Lihong Zhou, Lihuan Zhou, Lijun Zhou, Lili Zhou, Limin Zhou, Lin Zhou, Lina Zhou, Linda Zhou, Ling Zhou, Ling-Yun Zhou, Linglin Zhou, Lingshan Zhou, Lingyi Zhou, Lingyun Zhou, Linjun Zhou, Linnan Zhou, Linran Zhou, Lipeng Zhou, Liqun Zhou, Lisha Zhou, Lisheng Zhou, Liting Zhou, Liufang Zhou, Liuqing Zhou, Liuxin Zhou, Lixin Zhou, Liye Zhou, Long Zhou, Lu Zhou, Lufang Zhou, Luling Zhou, Luming Zhou, Lunni Zhou, Luo-Qi Zhou, Luting Zhou, M M Zhou, Maoge Zhou, Maotian Zhou, Mei Zhou, Meijing Zhou, Meilan Zhou, Meiqi Zhou, Meirong Zhou, Meiyi Zhou, Meng-Tao Zhou, Meng-Yao Zhou, Menghua Zhou, Mengkai Zhou, Menglong Zhou, Mengna Zhou, Mengqi Zhou, Mengqian Zhou, Mengze Zhou, Mi Zhou, Miao Zhou, Min Zhou, Ming Zhou, Ming-Ju Zhou, Ming-Ming Zhou, Ming-Sheng Zhou, Mingfeng Zhou, Minglei Zhou, Minglian Zhou, Mingmei Zhou, Mingming Zhou, Mingping Zhou, Mingqi Zhou, Minling Zhou, Minyi Zhou, Molin Zhou, Na Zhou, Nan Zhou, Neng Zhou, Ni Zhou, Nian Zhou, Nianwei Zhou, Ning Zhou, Ningying Zhou, Niuniu Zhou, P Zhou, Pei Zhou, Peng Zhou, Penghui Zhou, Pijun Zhou, Ping Zhou, Ping-Kun Zhou, Pingkun Zhou, Pingxi Zhou, Pingxin Zhou, Puhui Zhou, Q Zhou, Qi Zhou, Qian Zhou, Qiang Zhou, Qianxin Zhou, Qiao Zhou, Qiaoxia Zhou, Qidong Zhou, Qin Zhou, Qin-Yi Zhou, Qing Zhou, Qing-Bing Zhou, Qing-Qing Zhou, Qingbing Zhou, Qingbo Zhou, Qingchun Zhou, Qinghua Zhou, Qingniao Zhou, Qingnv Zhou, Qingping Zhou, Qingtong Zhou, Qingxin Zhou, Qingyu Zhou, Qiong Zhou, Qiu-Min Zhou, Qiu-Zhi Zhou, Qiyang Zhou, Qiyin Zhou, Quan Zhou, Qun Zhou, R B Zhou, Ranran Zhou, Raorao Zhou, Ren Zhou, Rong Zhou, Rong-Yan Zhou, Rongbin Zhou, Rongjia Zhou, Rongxian Zhou, Rongxuan Zhou, Rongyan Zhou, Rouxi Zhou, Ru Zhou, Ruchen Zhou, Rui Zhou, Ruihai Zhou, Ruijun Zhou, Ruimei Zhou, Ruisi Zhou, Runjin Zhou, Ruyi Zhou, S A Zhou, S R Zhou, S Zhou, S-G Zhou, Sa Zhou, Sanshun Zhou, Sha Zhou, Shanshan Zhou, Shao-Lai Zhou, Shaobo Zhou, Shaoli Zhou, Shaolong Zhou, Sheng-Nan Zhou, Shenghua Zhou, Shenghui Zhou, Shengwen Zhou, Shengyang Zhou, Shengyi Zhou, Shenping Zhou, Shiao Zhou, Shibo Zhou, Shiyi Zhou, Shu Zhou, Shuaishuai Zhou, Shuaiyang Zhou, Shuang Zhou, Shuling Zhou, Shumin Zhou, Shun Zhou, Shuo Zhou, Si Zhou, Si-Qi Zhou, Siquan Zhou, Sirui Zhou, Song Zhou, Songhui Zhou, Sufang Zhou, Sumei Zhou, Suqing Zhou, Suzhen Zhou, T Zhou, Tai-Cheng Zhou, Taimei Zhou, Tao Zhou, Tengxiao Zhou, Ti Zhou, Tian-Li Zhou, Tianhua Zhou, Tianqiong Zhou, Tianrong Zhou, Tianxing Zhou, Tianyan Zhou, Tianyu Zhou, Tiger Zhou, Ting Zhou, Tingting Zhou, Tong Zhou, Vincent Zhou, W Zhou, Wan-hao Zhou, Wang Zhou, Wei Zhou, Weihua Zhou, Weihui Zhou, Weijiao Zhou, Weijie Zhou, Weiming Zhou, Weinan Zhou, Weiqiang Zhou, Weishang Zhou, Weiwei Zhou, Weiying Zhou, Wen Zhou, Wen-Chao Zhou, Wen-Hao Zhou, Wen-Jie Zhou, Wen-Quan Zhou, Wenbin Zhou, Wenbo Zhou, Wenchao Zhou, Wenfang Zhou, Wenhao Zhou, Wenjie Zhou, Wenjing Zhou, Wenke Zhou, Wenqing Zhou, Wenrong Zhou, Wenwen Zhou, Wenxing Zhou, Wenyu Zhou, Wenzong Zhou, Wesley Zhou, Wu Zhou, Wuduo Zhou, Wuyuan Zhou, X F Zhou, X Q Zhou, X-T Zhou, Xi Zhou, Xia Zhou, Xia-Bo Zhou, Xiang Zhou, Xiangda Zhou, Xiangdong Zhou, Xianghai Zhou, Xiangrong Zhou, Xianguo Zhou, Xiangyu Zhou, Xiangyuan Zhou, Xianhu Zhou, Xianhua Zhou, Xianhui Zhou, Xianjing Zhou, Xianliang Zhou, Xianxiao Zhou, Xiao Zhou, Xiao-Hai Zhou, Xiao-Ting Zhou, Xiao-Yu Zhou, Xiaobo Zhou, Xiaochuan Zhou, Xiaochun Zhou, Xiaofeng Zhou, Xiaohai Zhou, Xiaohan Zhou, Xiaohui Zhou, Xiaojing Zhou, Xiaolei Zhou, Xiaoli Zhou, Xiaolin Zhou, Xiaoling Zhou, Xiaomao Zhou, Xiaoming Zhou, Xiaonan Zhou, Xiaopu Zhou, Xiaoqian Zhou, Xiaorong Zhou, Xiaorui Zhou, Xiaoshu Zhou, Xiaosu Zhou, Xiaotong Zhou, Xiaowen Zhou, Xiaoxi Zhou, Xiaoxia Zhou, Xiaoxue Zhou, Xiaoyan Zhou, Xiaoye Zhou, Xiaoying Zhou, Xiaozhong Zhou, Xidan Zhou, Xin Tong Zhou, Xin Zhou, Xin-Rong Zhou, Xin-Yu Zhou, Xin-Yue Zhou, Xingtao Zhou, Xinhong Zhou, Xinhua Zhou, Xinming Zhou, Xinyan Zhou, Xinyao Zhou, Xinyi Zhou, Xinyue Zhou, Xinzhi Zhou, Xiqiu Zhou, Xiu-Ping Zhou, Xiuhong Zhou, Xiuling Zhou, Xiuping Zhou, Xiuteng Zhou, Xiyi Zhou, Xu Yu Zhou, Xu Zhou, Xu-Hua Zhou, Xuan Zhou, Xuanchen Zhou, Xuchang Zhou, Xue Dong Zhou, Xue Zhou, Xue-Yan Zhou, Xuedong Zhou, Xuefeng Zhou, Xuejie Zhou, Xueli Zhou, Xueliang Zhou, Xueqin Zhou, Xueqing Zhou, Xueshi Zhou, Xujie Zhou, Xun Zhou, Xuyu Zhou, Y J Zhou, Y Zhou, Y-L Zhou, Yachuan Zhou, Yadi Zhou, Yahui Zhou, Yajun Zhou, Yan Zhou, Yan-Yan Zhou, Yanbing Zhou, Yandong Zhou, Yanfen Zhou, Yang Zhou, Yangbo Zhou, Yangying Zhou, Yanhao Zhou, Yanheng Zhou, Yanhua Zhou, Yanjiao Zhou, Yanjie Zhou, Yanli Zhou, Yanling Zhou, Yanmeng Zhou, Yanqiu Zhou, Yanrong Zhou, Yanyi Zhou, Yao Zhou, Yaping Zhou, Yaqi Zhou, Yating Zhou, Yeyun Zhou, Yi Zhou, Yi-Hui Zhou, Yi-Jiang Zhou, Yichao Zhou, Yidan Zhou, Yifa Zhou, Yifeng Zhou, Yinan Zhou, Ying Zhou, Ying-Hui Zhou, Yinghui Zhou, Yingjie Zhou, Yingmin Zhou, Yingshi Zhou, Yiqing Zhou, Yitian Zhou, Yong Zhou, Yong-Gang Zhou, Yong-Hui Zhou, Yong-an Zhou, Yongbing Zhou, Yongcan Zhou, Yonghua Zhou, Yongjian Zhou, Yongqiang Zhou, Yongtao Zhou, Yongxin Zhou, Yongzhi Zhou, You Lang Zhou, You Zhou, You-Li Zhou, Youping Zhou, Yu Zhou, Yu-Bao Zhou, Yu-Ning Zhou, Yu-Qi Zhou, Yuan Zhou, Yuanyuan Zhou, Yubin Zhou, Yudong Zhou, Yue Zhou, Yueping Zhou, Yuetao Zhou, Yufei Zhou, Yuhan Zhou, Yuhuan Zhou, Yujia Zhou, Yujie Zhou, Yun Zhou, Yun-Fei Zhou, Yun-Tao Zhou, Yunfang Zhou, Yunfeng Zhou, Yunhui Zhou, Yunqian Zhou, Yunxia Zhou, Yunxiang Zhou, Yunyun Zhou, Yunzhen Zhou, Yuqi Zhou, Yuqiao Zhou, Yuqing Zhou, Yuqiu Zhou, Yushan Zhou, Yuting Zhou, Yutong Zhou, Yuxin Zhou, Yuzhi Zhou, Zechen Zhou, Zefeng Zhou, Zenghui Zhou, Zengyuan Zhou, Zengzi Zhou, Zewei Zhou, Zhan Zhou, Zhaokai Zhou, Zhechong Zhou, Zhen Zhou, Zheng Zhou, Zheng-Jun Zhou, Zheng-Yang Zhou, Zhengyang Zhou, Zhengzhong Zhou, Zhenhua Zhou, Zhenlei Zhou, Zhenying Zhou, Zhenyu Zhou, Zheyi Zhou, Zhi Dong Zhou, Zhi Zhou, Zhi-Dong Zhou, Zhi-Gang Zhou, Zhi-Hang Zhou, Zhi-Jiao Zhou, Zhi-Xiang Zhou, Zhi-Yong Zhou, Zhibo Zhou, Zhicheng Zhou, Zhifeng Zhou, Zhiguang Zhou, Zhihang Zhou, Zhihao Zhou, Zhiheng Zhou, Zhihui Zhou, Zhijiao Zhou, Zhijun Zhou, Zhimin Zhou, Zhipeng Zhou, Zhiqin Zhou, Zhiqun Zhou, Zhiwei Zhou, Zhixiang Zhou, Zhiyi Zhou, Zhiyong Zhou, Zhiyu Zhou, Zhongbo Zhou, Zhongjiang Zhou, Zhongkai Zhou, Zhongqiu Zhou, Zhongtao Zhou, Zhongxing Zhou, Zhongyin Zhou, Zhou Zhou, Zhu Zhou, Zhuoming Zhou, Zi-Yang Zhou, Zi-Yi Zhou, Zihan Zhou, Zihao Zhou, Zihua Zhou, Zijun Zhou, Zili Zhou, Ziliang Zhou, Zilin Zhou, Zilong Zhou, Zipeng Zhou, Ziqing Zhou, Ziwei Zhou, Ziyan Zhou, Ziyue Zhou, Ziyun Zhou, Zongkai Zhou, Zunchun Zhou, Zuomin Zhou, Zuoqiong Zhou, Zuping Zhou
articles
Juan Wang, Dan Li, Wenzhi Shen +11 more · 2020 · Anatomical record (Hoboken, N.J. : 2007) · Wiley · added 2026-04-24
Breast cancer is one of the most common types of cancer in women. Although the mortality rate of breast cancer has fallen over the past 10 years, effective treatments that reduce the occurrence of bre Show more
Breast cancer is one of the most common types of cancer in women. Although the mortality rate of breast cancer has fallen over the past 10 years, effective treatments that reduce the occurrence of breast cancer metastasis remain lacking. In this study, we explored the role of receptor for hyaluronan mediated motility (RHAMM) and the associated signaling pathway in cell migration in luminal A breast cancer. We first examined RHAMM expression levels using human breast tissue microarray and patient breast tissues. We then studied the role of RHAMM in migration in luminal A breast cancer using loss-of-function and gain-of-function strategies in in vitro models and confirmed these findings in an in vivo model. Finally, we investigated signaling molecules that play a role in cell migration using western blot. Our results demonstrated the following: (a) RHAMM shows high expression levels in malignant breast tissue, (b) RHAMM shows low expression levels in luminal A breast cancer compared to other subtypes of breast cancer, (c) RHAMM inhibits cell migration in luminal A breast cancer, and (d) RHAMM inhibits cell migration via the AKT/GSK3β/Snail axis in luminal A breast cancer. This study demonstrates a novel role of RHAMM in cell migration in luminal A breast cancer and suggests that therapeutic strategies involving RHAMM should be considered for various subtypes of breast cancer. Show less
no PDF DOI: 10.1002/ar.24321
SNAI1
Farjana Yeasmin Khusbu, Xi Zhou, Mridul Roy +3 more · 2020 · The international journal of biochemistry & cell biology · Elsevier · added 2026-04-24
Although the early diagnosis of prostate cancer (PCa) enhances life expectancy with a 5-year survival rate of 100 %, metastasized-PCa is the fundamental reason for death by PCa, hence requires an adva Show more
Although the early diagnosis of prostate cancer (PCa) enhances life expectancy with a 5-year survival rate of 100 %, metastasized-PCa is the fundamental reason for death by PCa, hence requires an advanced and target-directed treatment strategy. Metastasis is considered to be initiated with the epithelial-mesenchymal transition (EMT) event in which tumor cells change their epithelial characteristics into mesenchymal form and exacerbates the cancer progression. Herein, we investigated the effect and mechanism of resveratrol function in PCa cell proliferation and migration and reported that TNF-receptor associated factor 6 (TRAF6), an unconventional E3 ligase, is a key mediator of resveratrol function to inhibit PCa cell growth and proliferation and targeted for lysosomal degradation by resveratrol. MTT and cell counting demonstrated that resveratrol inhibited the viability and proliferation in DU145 and PC3 cells. Resveratrol (50 μM) mediated the degradation of TRAF6 which in turn facilitated repression of the NF-κB pathway. Also, wound healing and transwell migration assays and level of EMT-related proteins showed that resveratrol used TRAF6, at least in part to inhibit cell migration. Overexpression of TRAF6 augmented EMT in PCa by upregulating the expression of transcription factor SLUG. Moreover, TRAF6 overexpression was closely associated with EMT process through the NF-κB pathway. Our exploration exhibited that resveratrol may inhibit EMT through the TRAF6/NF-κB/SLUG axis. Altogether, this study represents that TRAF6 acts as an intermediary of resveratrol action to suppress PCa cell proliferation and migration, and concerns future attention to obtain as a therapeutic target for the treatment of PCa. Show less
no PDF DOI: 10.1016/j.biocel.2019.105644
SNAI1
Jianqing Wang, Chenxi He, Peng Gao +9 more · 2020 · Oncogene · Nature · added 2026-04-24
Prostate cancer is the most common malignancy in men in developed countries. Overexpression of enhancer of zeste homolog 2 (EZH2), the major histone H3 lysine 27 methyltransferase, has been connected Show more
Prostate cancer is the most common malignancy in men in developed countries. Overexpression of enhancer of zeste homolog 2 (EZH2), the major histone H3 lysine 27 methyltransferase, has been connected to prostate cancer malignancy. However, its downstream genes and pathways have not been well established. Here, we show tumor suppressor Hepatocyte Nuclear Factor 1β (HNF1B) as a direct downstream target of EZH2. EZH2 binds HNF1B locus and suppresses HNF1B expression in prostate cancer cell lines, which is further supported by the reverse correlation between EZH2 and HNF1B expression in clinical samples. Consistently, restored HNF1B expression significantly suppresses EZH2-mediated overgrowth and EMT processes, including migration and invasion of prostate cancer cell lines. Mechanistically, we find that HNF1B primarily binds the promoters of thousands of target genes, and differentially regulates the expression of 876 genes. We also identify RBBP7/RbAP46 as a HNF1B interacting protein which is required for HNF1B-mediated repression of SLUG expression and EMT process. Importantly, we find that higher HNF1B expression strongly predicts better prognosis of prostate cancer, alone or together with lower EZH2 expression. Taken together, we have established a previously underappreciated axis of EZH2-HNF1B-SLUG in prostate cancer, and also provide evidence supporting HNF1B as a potential prognosis marker for metastatic prostate cancer. Show less
no PDF DOI: 10.1038/s41388-019-1065-2
SNAI1
Jinhong Wie, Apoorva Bharthur, Morgan Wolfgang +7 more · 2020 · Nature communications · Nature · added 2026-04-24
The sodium-leak channel NALCN forms a subthreshold sodium conductance that controls the resting membrane potentials of neurons. The auxiliary subunits of the channel and their functions in mammals are Show more
The sodium-leak channel NALCN forms a subthreshold sodium conductance that controls the resting membrane potentials of neurons. The auxiliary subunits of the channel and their functions in mammals are largely unknown. In this study, we demonstrate that two large proteins UNC80 and UNC79 are subunits of the NALCN complex. UNC80 knockout mice are neonatal lethal. The C-terminus of UNC80 contains a domain that interacts with UNC79 and overcomes a soma-retention signal to achieve dendritic localization. UNC80 lacking this domain, as found in human patients, still supports whole-cell NALCN currents but lacks dendritic localization. Our results establish the subunit composition of the NALCN complex, uncover the inter-subunit interaction domains, reveal the functional significance of regulation of dendritic membrane potential by the sodium-leak channel complex, and provide evidence supporting that genetic variations found in individuals with intellectual disability are the causes for the phenotype observed in patients. Show less
no PDF DOI: 10.1038/s41467-020-17105-8
UNC79
Chuanman Zhou, Jintao Luo, Xiaohui He +4 more · 2020 · G3 (Bethesda, Md.) · added 2026-04-24
NALCN (
no PDF DOI: 10.1534/g3.119.400692
UNC79
Yanyan Jiang, Meng Yu, Jing Chen +9 more · 2020 · Brain and behavior · Wiley · added 2026-04-24
Genetic mutations associated with early-onset Parkinson's disease (EOPD) vary widely among different ethnicities. We detected the genes associated with EOPD in a Chinese cohort using next-generation s Show more
Genetic mutations associated with early-onset Parkinson's disease (EOPD) vary widely among different ethnicities. We detected the genes associated with EOPD in a Chinese cohort using next-generation sequencing (NGS) combined with multiplex ligation-dependent probe amplification (MLPA) and analyzed the phenotypic characteristics of the mutation carriers. Cohort of 23 sporadic EOPD patients (onset age ≤ 45 years) were recruited. Genetic causes were identified by a targeted NGS panel containing 136 known extrapyramidal disease-causative genes. Multiplications or deletions of PD-causing genes were detected using the MLPA method. Demographic and clinical data were obtained, analyzed, and compared between patients with and those without Parkin gene variants. We identified 14 pathogenic or likely pathogenic variants (12 in Parkin, 1 in LRRK2, and 1 in VPS13C) in 10 patients (43.5%) and 8 rare variants of uncertain significance in 9 patients (39.1%). Parkin (34.8%) was the most common causative gene among our patients cohort, and exon deletion (62.5%) was the main type of variant. Patients with Parkin mutations had a younger age of onset, longer delay in diagnosis, slower disease progression, higher frequency of hyperreflexia, fatigue, and less hyposmia compared to patients without Parkin mutations. Our results revealed a higher prevalence of Parkin mutations in Chinese sporadic EOPD patients, and notably, exon deletion was the most common type of mutation. EOPD patients with Parkin mutations showed unique clinical characteristics. Show less
no PDF DOI: 10.1002/brb3.1765
VPS13C
Hong Che, Weilai He, Junbo Feng +6 more · 2020 · Cell biochemistry and function · Wiley · added 2026-04-24
E3 ubiquitin ligase gene, WWP2, is associated with acute kidney injury (AKI). This research was conducted to explore the role of WWP2 in AKI. AKI cell model was produced in human renal proximal tubula Show more
E3 ubiquitin ligase gene, WWP2, is associated with acute kidney injury (AKI). This research was conducted to explore the role of WWP2 in AKI. AKI cell model was produced in human renal proximal tubular epithelial cell line (HK-2) by ischemia-reperfusion (IR) injury. CCK8 and flow cytometry assay were performed to explore the influence of WWP2 overexpression on cell proliferation and apoptosis of IR-induced HK-2 cells. Quantitative real-time PCR and immunoblotting (IB) were performed to assess the gene and protein expression. Then, the influence of WWP2 on p53 ubiquitylation and degradation was estimated by immunoprecipitation assay. Our data indicated that WWP2 was down-regulated and p53 was up-regulated in IR-induced HK-2 cells. WWP2 overexpression promoted proliferation and inhibited apoptosis of IR-induced HK-2 cells. And WWP2 interacted with p53 and regulated p53 ubiquitylation and degradation. Furthermore, the influence of WWP2 on cell proliferation and apoptosis was rescued by MG132 (proteasome inhibitor) treatment. In conclusion, our work described for the first time the role of WWP2 in AKI, showing that WWP2 ameliorated AKI by mediating p53 ubiquitylation and degradation. Moreover, the study offers some important insights into the occurrence of AKI and WWP2 may be a novel target of AKI treatment. SIGNIFICANCE OF THE STUDY: Our data elaborates that WWP2 has protective effect against AKI by mediating p53 ubiquitylation and degradation. Thus, WWP2 might be a therapeutic target for AKI. Show less
no PDF DOI: 10.1002/cbf.3533
WWP2
Binbin Wang, Pinghua Li, Wuduo Zhou +8 more · 2019 · Animals : an open access journal from MDPI · MDPI · added 2026-04-24
The present study aimed to identify the molecular markers for genes that influence intramuscular fat content (IFC), but not average backfat thickness (ABT). A total of 330 Suhuai pigs were slaughtered Show more
The present study aimed to identify the molecular markers for genes that influence intramuscular fat content (IFC), but not average backfat thickness (ABT). A total of 330 Suhuai pigs were slaughtered, and measurements of IFC and ABT were obtained. Phenotypic and genetic correlations between IFC and ABT were calculated. Thirteen single nucleotide polymorphisms (SNPs) among 12 candidate genes for IFC were analyzed, including Show less
📄 PDF DOI: 10.3390/ani9110858
MC4R
Anwar Mulugeta, Ang Zhou, Karani S Vimaleswaran +2 more · 2019 · Depression and anxiety · Wiley · added 2026-04-24
This study aimed to explore the association between depression and body mass index (BMI), and to investigate whether genetic susceptibility to high BMI is different among individuals with or without d Show more
This study aimed to explore the association between depression and body mass index (BMI), and to investigate whether genetic susceptibility to high BMI is different among individuals with or without depression. We used data on 251,125 individuals of white British ancestry from the UK Biobank. We conducted Mendelian randomization (MR) analysis to test for a causal association between depression and BMI using a major depressive disorder (MDD)-related genetic risk score (GRS We found observational and genetic evidence for an association between depression and BMI (MR beta: 0.09, 95% confidence interval [CI] 0.04-0.13). Further, the contribution of genetic risk to high BMI was higher among individuals with depression compared to controls. Carrying 10 additional BMI increasing alleles was associated with 0.24 standard deviation (SD; 95%CI 0.23-0.25) higher BMI among depressed individuals compared to 0.20 SD (95%CI 0.19-0.21) higher in controls, which corresponds to 3.4 kg and 2.8 kg extra weight for an individual of average height. Amongst the individual loci, the evidence for interaction was most notable for a variant near MC4R, a gene known to affect both appetite regulation and the hypothalamic-pituitary adrenal axis (p Genetic predisposition to high BMI was higher among depressed than to nondepressed individuals. This study provides support for a possible role of MC4R in the link between depression and obesity. Show less
no PDF DOI: 10.1002/da.22963
MC4R
Yuhang Chen, Huikun Liu, Leishen Wang +8 more · 2019 · The American journal of clinical nutrition · Oxford University Press · added 2026-04-24
A history of gestational diabetes mellitus (GDM) has been related to an elevated risk of type 2 diabetes. The melanocortin-4 receptor (MC4R) genotype has been related to glycemic changes in women with Show more
A history of gestational diabetes mellitus (GDM) has been related to an elevated risk of type 2 diabetes. The melanocortin-4 receptor (MC4R) genotype has been related to glycemic changes in women with prior GDM. The objective of this study was to analyze whether lifestyle intervention modified the association between the MC4R genotype and changes in insulin sensitivity among women with prior GDM. We genotyped MC4R rs6567160 and measured glucose and insulin in fasting plasma samples at baseline and during the first 2 follow-up visits in 1128 women with prior GDM. They were randomly assigned to either a 4-y lifestyle intervention involving both diet and physical activity or a control group from a randomized clinical trial, the Tianjin Gestational Diabetes Mellitus Prevention Program. We analyzed the interaction between the MC4R genotype and lifestyle intervention on changes in insulin resistance. From baseline to 1.28 y, the MC4R genotype was related to changes in fasting insulin, HOMA-IR, and homeostasis model assessment of β cell function (HOMA-B) in the intervention group. Each risk allele (C) of rs6567160 was associated with a 0.08-unit greater decrease in log(insulin), log(HOMA-IR), and log(HOMA-B) (P = 0.02, 0.04, and 0.04, respectively), whereas in the control group, each C allele tended to be associated with a greater increase in HOMA-IR (P = 0.09). We found significant interactions between the MC4R genotype and lifestyle intervention on 1.28-y changes in fasting insulin and HOMA-IR (P = 0.006 and 0.008, respectively), and such interaction remained significant when we analyzed the trajectory of changes in insulin and HOMA-IR from baseline to 2.55 y (both P = 0.03). The exploratory results from the first 2 follow-up visits indicate that women with prior GDM carrying a diabetes-increasing MC4R genotype (CC or TC) may obtain better improvement than the TT genotype in insulin resistance through lifestyle intervention. This trial was registered at clinicaltrials.gov as NCT01554358. Show less
no PDF DOI: 10.1093/ajcn/nqz121
MC4R
Yan Zhou, Francesco Leri, Malcolm J Low +1 more · 2019 · Pharmacology, biochemistry, and behavior · Elsevier · added 2026-04-24
A fixed dose combination of bupropion (BPP) and naltrexone (NTX), Contrave®, is an FDA approved pharmacotherapy for the treatment of obesity. A recent study found that combining BPP with low-dose NTX Show more
A fixed dose combination of bupropion (BPP) and naltrexone (NTX), Contrave®, is an FDA approved pharmacotherapy for the treatment of obesity. A recent study found that combining BPP with low-dose NTX reduced alcohol drinking in alcohol-preferring male rats. To explore potential pharmacological effects of the BPP + NTX combination on alcohol drinking, both male and female C57Bl/6J mice were tested on one-week drinking-in-the dark (DID) and three-week intermittent access (IA) models. Neuronal proopiomelanocortin (POMC) enhancer knockout (nPE Show less
📄 PDF DOI: 10.1016/j.pbb.2019.04.004
MC4R
Maria Caterina De Rosa, Alessandra Chesi, Shana McCormack +11 more · 2019 · The Journal of clinical endocrinology and metabolism · added 2026-04-24
Mutations in melanocortin receptor (MC4R) are the most common cause of monogenic obesity in children of European ancestry, but little is known about their prevalence in children from the minority popu Show more
Mutations in melanocortin receptor (MC4R) are the most common cause of monogenic obesity in children of European ancestry, but little is known about their prevalence in children from the minority populations in the United States. This study aims to identify the prevalence of MC4R mutations in children with severe early-onset obesity of African American or Latino ancestry. Participants were recruited from the weight management clinics at two hospitals and from the institutional biobank at a third hospital. Sequencing of the MC4R gene was performed by whole exome or Sanger sequencing. Functional testing was performed to establish the surface expression of the receptor and cAMP response to its cognate ligand α-melanocyte-stimulating hormone. Three hundred twelve children (1 to 18 years old, 50% girls) with body mass index (BMI) >120% of 95th percentile of Centers for Disease Control and Prevention 2000 growth charts at an age <6 years, with no known pathological cause of obesity, were enrolled. Eight rare MC4R mutations (2.6%) were identified in this study [R7S, F202L (n = 2), M215I, G252D, V253I, I269N, and F284I], three of which were not previously reported (G252D, F284I, and R7S). The pathogenicity of selected variants was confirmed by prior literature reports or functional testing. There was no significant difference in the BMI or height trajectories of children with or without MC4R mutations in this cohort. Although the prevalence of MC4R mutations in this cohort was similar to that reported for obese children of European ancestry, some of the variants were novel. Show less
no PDF DOI: 10.1210/jc.2018-02657
MC4R
David Karasik, M Carola Zillikens, Yi-Hsiang Hsu +154 more · 2019 · The American journal of clinical nutrition · Oxford University Press · added 2026-04-24
David Karasik, M Carola Zillikens, Yi-Hsiang Hsu, Ali Aghdassi, Kristina Akesson, Najaf Amin, Inês Barroso, David A Bennett, Lars Bertram, Murielle Bochud, Ingrid B Borecki, Linda Broer, Aron S Buchman, Liisa Byberg, Harry Campbell, Natalia Campos-Obando, Jane A Cauley, Peggy M Cawthon, John C Chambers, Zhao Chen, Nam H Cho, Hyung Jin Choi, Wen-Chi Chou, Steven R Cummings, Lisette C P G M de Groot, Phillip L De Jager, Ilja Demuth, Luda Diatchenko, Michael J Econs, Gudny Eiriksdottir, Anke W Enneman, Joel Eriksson, Johan G Eriksson, Karol Estrada, Daniel S Evans, Mary F Feitosa, Mao Fu, Christian Gieger, Harald Grallert, Vilmundur Gudnason, Launer J Lenore, Caroline Hayward, Albert Hofman, Georg Homuth, Kim M Huffman, Lise B Husted, Thomas Illig, Erik Ingelsson, Till Ittermann, John-Olov Jansson, Toby Johnson, Reiner Biffar, Joanne M Jordan, Antti Jula, Magnus Karlsson, Kay-Tee Khaw, Tuomas O Kilpeläinen, Norman Klopp, Jacqueline S L Kloth, Daniel L Koller, Jaspal S Kooner, William E Kraus, Stephen Kritchevsky, Zoltán Kutalik, Teemu Kuulasmaa, Johanna Kuusisto, Markku Laakso, Jari Lahti, Thomas Lang, Bente L Langdahl, Markus M Lerch, Joshua R Lewis, Christina Lill, Lars Lind, Cecilia Lindgren, Yongmei Liu, Gregory Livshits, Östen Ljunggren, Ruth J F Loos, Mattias Lorentzon, Jian'an Luan, Robert N Luben, Ida Malkin, Fiona E McGuigan, Carolina Medina-Gomez, Thomas Meitinger, Håkan Melhus, Dan Mellström, Karl Michaëlsson, Braxton D Mitchell, Andrew P Morris, Leif Mosekilde, Maria Nethander, Anne B Newman, Jeffery R O'Connell, Ben A Oostra, Eric S Orwoll, Aarno Palotie, Munro Peacock, Markus Perola, Annette Peters, Richard L Prince, Bruce M Psaty, Katri Räikkönen, Stuart H Ralston, Samuli Ripatti, Fernando Rivadeneira, John A Robbins, Jerome I Rotter, Igor Rudan, Veikko Salomaa, Suzanne Satterfield, Sabine Schipf, Chan Soo Shin, Albert V Smith, Shad B Smith, Nicole Soranzo, Timothy D Spector, Alena Stancáková, Kari Stefansson, Elisabeth Steinhagen-Thiessen, Lisette Stolk, Elizabeth A Streeten, Unnur Styrkarsdottir, Karin M A Swart, Patricia Thompson, Cynthia A Thomson, Gudmar Thorleifsson, Unnur Thorsteinsdottir, Emmi Tikkanen, Gregory J Tranah, André G Uitterlinden, Cornelia M Van Duijn, Natasja M van Schoor, Liesbeth Vandenput, Peter Vollenweider, Henry Völzke, Jean Wactawski-Wende, Mark Walker, Nicholas J Wareham, Dawn Waterworth, Michael N Weedon, H-Erich Wichmann, Elisabeth Widen, Frances M K Williams, James F Wilson, Nicole C Wright, Laura M Yerges-Armstrong, Lei Yu, Weihua Zhang, Jing Hua Zhao, Yanhua Zhou, Carrie M Nielson, Tamara B Harris, Serkalem Demissie, Douglas P Kiel, Claes Ohlsson Show less
Lean body mass (LM) plays an important role in mobility and metabolic function. We previously identified five loci associated with LM adjusted for fat mass in kilograms. Such an adjustment may reduce Show more
Lean body mass (LM) plays an important role in mobility and metabolic function. We previously identified five loci associated with LM adjusted for fat mass in kilograms. Such an adjustment may reduce the power to identify genetic signals having an association with both lean mass and fat mass. To determine the impact of different fat mass adjustments on genetic architecture of LM and identify additional LM loci. We performed genome-wide association analyses for whole-body LM (20 cohorts of European ancestry with n = 38,292) measured using dual-energy X-ray absorptiometry) or bioelectrical impedance analysis, adjusted for sex, age, age2, and height with or without fat mass adjustments (Model 1 no fat adjustment; Model 2 adjustment for fat mass as a percentage of body mass; Model 3 adjustment for fat mass in kilograms). Seven single-nucleotide polymorphisms (SNPs) in separate loci, including one novel LM locus (TNRC6B), were successfully replicated in an additional 47,227 individuals from 29 cohorts. Based on the strengths of the associations in Model 1 vs Model 3, we divided the LM loci into those with an effect on both lean mass and fat mass in the same direction and refer to those as "sumo wrestler" loci (FTO and MC4R). In contrast, loci with an impact specifically on LM were termed "body builder" loci (VCAN and ADAMTSL3). Using existing available genome-wide association study databases, LM increasing alleles of SNPs in sumo wrestler loci were associated with an adverse metabolic profile, whereas LM increasing alleles of SNPs in "body builder" loci were associated with metabolic protection. In conclusion, we identified one novel LM locus (TNRC6B). Our results suggest that a genetically determined increase in lean mass might exert either harmful or protective effects on metabolic traits, depending on its relation to fat mass. Show less
no PDF DOI: 10.1093/ajcn/nqy272
MC4R
Yuxin Zhou, Liyan Qiu, Ashley Sterpka +3 more · 2019 · Frontiers in cellular neuroscience · Frontiers · added 2026-04-24
Type III adenylyl cyclase (AC3,
📄 PDF DOI: 10.3389/fncel.2019.00034
ADCY3
Bingqing Hui, Hao Ji, Yetao Xu +5 more · 2019 · Cell death & disease · Nature · added 2026-04-24
Long noncoding RNAs (lncRNAs) have been reported to be involved in a variety of human diseases, including cancers. However, their mechanisms have not yet been fully elucidated. We investigated lncRNA Show more
Long noncoding RNAs (lncRNAs) have been reported to be involved in a variety of human diseases, including cancers. However, their mechanisms have not yet been fully elucidated. We investigated lncRNA changes that may be associated with pancreatic cancer (PC) by analyzing published microarray data, and identified AGAP2-AS1 as a relatively overexpressed lncRNA in PC tissues. qRT-PCR assays were performed to examine expression levels of AGAP2-AS1. MTT assays, colony formation assays, and EdU assays were used to determine the proliferative capacity of cells. Flow cytometry and TUNEL assays were used to study the regulation of AGAP2-AS1 in the cell cycle and apoptosis. Transwell experiments were used to study changes in cell invasion and metastasis, and a nude mouse model was established to assess the effects of AGAP2-AS1 on tumorigenesis in vivo. RNA sequencing was performed to probe AGAP2-AS1-related pathways. Subcellular fractionation and FISH assays were used to determine the distribution of AGAP2-AS1 in PC cells, and RIP and ChIP were used to determine the molecular mechanism of AGAP2-AS1-mediated regulation of potential target genes. Increased expression of AGAP2-AS1 was associated with tumor size and pathological stage progression in patients with PC. RREB1 was found to activate transcription of AGAP2-AS1 in PC cells. AGAP2-AS1 affected proliferation, apoptosis, cycle arrest, invasion, and metastasis of PC cells in vitro, and AGAP2-AS1 regulated PC proliferation in vivo. Furthermore, AGAP2-AS1 epigenetically inhibited the expression of ANKRD1 and ANGPTL4 by recruiting zeste homolog 2 (EZH2), thereby promoting PC proliferation and metastasis. In summary, our data show that RREB1-induced upregulation of AGAP2-AS1 regulates cell proliferation and migration in PC partly through suppressing ANKRD1 and ANGPTL4 by recruiting EZH2. AGAP2-AS1 represents a potential target for the diagnosis and treatment of PC in the future. Show less
📄 PDF DOI: 10.1038/s41419-019-1384-9
ANGPTL4
Rui Zhang, Zihong Pan, Xiaoyu Wang +4 more · 2019 · Acta biochimica et biophysica Sinica · Oxford University Press · added 2026-04-24
Propamocarb (PM) is a pesticide that is widely used to protect cucumbers and other plants from downy mildew. Recently, some studies indicated that PM exposure had potential toxic effects in animals. I Show more
Propamocarb (PM) is a pesticide that is widely used to protect cucumbers and other plants from downy mildew. Recently, some studies indicated that PM exposure had potential toxic effects in animals. In this study, adult male zebrafish were exposed to 100 and 1000 μg/l PM for 7 days to assess its effects on metabolism and the gut microbiota. We observed a significant decrease in triglyceride (TG) in the livers of zebrafish that were exposed to 1000 μg/l PM for 7 days. At the same time, some genes related to glycolysis and lipid metabolism in the livers of zebrafish, including hexokinase-1 (HK1), pyruvate kinase (PK), acyl-CoA oxidase (Aco), peroxisome proliferator activated receptor alpha (Ppar-α), apolipoprotein A-IV-like (Apo), Acetyl CoA carboxylase-1 (Acc1), diacylglycerol acyltransferase (Dgat), and fatty acid synthase (Fas), were also decreased significantly after PM exposure. Based on GC-MS metabolomics analysis, a total of 48 metabolites changed significantly in the 1000 μg/l PM treatment group in comparison with the control group. These altered metabolites were mainly associated with the glycolysis, amino acid metabolism, and lipid metabolism pathways. Interestingly, we further found that the 1000 μg/l PM treatment group also showed significant elevations in Proteobacteria, Bacteroidetes, and Firmicutes at the phylum level. Sequencing of the 16S rRNA gene in the V3-V4 region also showed a significant change in the abundance and diversity of the gut microbiota in the 1000 μg/l PM treatment group. Our results indicated that exposure to PM for a short time could induce hepatic metabolic disorders and gut microbiota dysbiosis in adult male zebrafish. Show less
no PDF DOI: 10.1093/abbs/gmy153
APOA4
Jun-Yu Zhou, Mi Young Song, Sunmin Park · 2019 · The British journal of nutrition · added 2026-04-24
Metabolic syndrome (MetS) risk is influenced by genetic and environmental factors. The present study explored genetic risk scores (GRS) of genetic variants that influence the MetS and the effect of in Show more
Metabolic syndrome (MetS) risk is influenced by genetic and environmental factors. The present study explored genetic risk scores (GRS) of genetic variants that influence the MetS and the effect of interactions between GRS and nutrient intake on MetS risk. The genetic variants that influence MetS risk were selected by genome-wide association study after adjusting for age, sex, area of residence and BMI in 8840 middle-aged adults. GRS were calculated by summing the risk alleles of the selected SNP and divided into low (0-1), medium (2-3) and high (4-7) risk groups, and the relationships between the MetS and GRS were determined by logistic regression after adjusting covariates involved in MetS risk. We also analysed the interaction between GRS and lifestyles. Four genetic variants (APOA5_rs651821, EFCAB4B_rs4766165, ZNF259_rs2160669 and APOBEC1_rs10845640) were selected because they increased MetS risk after adjusting for covariates. Individuals with medium-GRS and high-GRS alleles had a higher MetS risk by 1·48- and 2·23-fold, respectively, compared with those with low-GRS after adjusting for covariates. The increase in MetS risk was mainly related to serum TAG and HDL-cholesterol concentrations. The GRS had an interaction with carbohydrate (CHO) and Na intakes and daily physical activities for MetS risk. In conclusion, Asian middle-aged adults with high-GRS alleles were at increased MetS risk mainly due to dyslipidaemia. High daily physical activity (≥1 h moderate activity per d) reduced the MetS risk but a low-CHO diet (<65 % of total energy intake) increased the risk in carriers with high-GRS alleles. Low Na intake (<1·6 g Na intake/4 MJ) did not decrease its risk. Show less
no PDF DOI: 10.1017/S0007114519001752
APOA5
Martin Adiels, Marja-Riitta Taskinen, Elias Björnson +12 more · 2019 · Diabetes, obesity & metabolism · Blackwell Publishing · added 2026-04-24
To investigate how apolipoprotein C-III (apoC-III) metabolism is altered in subjects with type 2 diabetes, whether the perturbed plasma triglyceride concentrations in this condition are determined pri Show more
To investigate how apolipoprotein C-III (apoC-III) metabolism is altered in subjects with type 2 diabetes, whether the perturbed plasma triglyceride concentrations in this condition are determined primarily by the secretion rate or the removal rate of apoC-III, and whether improvement of glycaemic control using the glucagon-like peptide-1 analogue liraglutide for 16 weeks modifies apoC-III dynamics. Postprandial apoC-III kinetics were assessed after a bolus injection of [5,5,5- Improved glycaemic control by liraglutide therapy for 16 weeks significantly reduced apoC-III secretion rate (561 ± 198 vs. 652 ± 196 mg/d, P = 0.03) and apoC-III levels (10.0 ± 3.8 vs. 11.7 ± 4.3 mg/dL, P = 0.035) in subjects with type 2 diabetes. Change in apoC-III secretion rate was significantly associated with the improvement in indices of glucose control (r = 0.67; P = 0.009) and change in triglyceride area under the curve (r = 0.59; P = 0.025). In line with this, the apoC-III secretion rate was higher in subjects with type 2 diabetes compared with BMI-matched non-diabetic subjects (676 ± 208 vs. 505 ± 174 mg/d, P = 0.042). The results reveal that the secretion rate of apoC-III is associated with elevation of triglyceride-rich lipoproteins in subjects with type 2 diabetes, potentially through the influence of glucose homeostasis on the production of apoC-III. Show less
no PDF DOI: 10.1111/dom.13744
APOC3
Zewen Song, Zhaomei Yu, Limin Chen +3 more · 2019 · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · Elsevier · added 2026-04-24
Micro-RNAs regulate multiple biological behaviors of cancers, making them potential targets of new cancer therapies. MiR-1181 has been demonstrated to perform oncogenic or tumor-suppressing function i Show more
Micro-RNAs regulate multiple biological behaviors of cancers, making them potential targets of new cancer therapies. MiR-1181 has been demonstrated to perform oncogenic or tumor-suppressing function in a tissue-dependent way, but its role in hepatocellular carcinoma (HCC) was unclear. Here, we showed that miR-1181 was significantly overexpressed in HCC tissues when compared with tumor-adjacent normal ones or normal liver tissues from donated organ, and that inhibition of miR-1181 could repress the growth of HCC cells. Through bioinformatics analysis and luciferase reporter assays, we found that axis inhibition protein 1 (AXIN1) was a direct target of miR-1181, and the expression of AXIN1 showed a negative correlation with that of miR-1181 in HCC. Therefore, these data indicated an oncogenic function of miRNA-1181 in the development of HCC and a potential target for the clinical treatment of HCC. Show less
no PDF DOI: 10.1016/j.biopha.2019.109397
AXIN1
Qin Li, Peng Zhang, Yanyun Wang +6 more · 2019 · Disease markers · added 2026-04-24
Previous evidence has indicated that the reduction of axis inhibition protein 1 ( Three hundred and sixteen BC patients and 419 healthy controls had been enrolled. Polymerase chain reaction-restrictio Show more
Previous evidence has indicated that the reduction of axis inhibition protein 1 ( Three hundred and sixteen BC patients and 419 healthy controls had been enrolled. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used for genotyping three tag single-nucleotide polymorphisms (SNPs) of Our data revealed that three tag SNPs were associated with an increased risk of BC (rs12921862: The Show less
📄 PDF DOI: 10.1155/2019/3949343
AXIN1
Yan Zhang, Yanyun Wang, Xingming Huang +7 more · 2019 · Biomarkers in medicine · added 2026-04-24
no PDF DOI: 10.2217/bmm-2018-0306
AXIN1
Kai Li, Yue Zhong, Ying Peng +6 more · 2019 · DNA and cell biology · added 2026-04-24
Dilated cardiomyopathy (DCM) is a common type of cardiomyopathy. The pathogenesis of DCM remains unclear and involves varied genes.
no PDF DOI: 10.1089/dna.2018.4567
AXIN1
Yachuan Zhou, Bing Shu, Rong Xie +6 more · 2019 · Journal of cellular physiology · Wiley · added 2026-04-24
Osteoarthritis (OA) in the temporomandibular joint (TMJ) is a degenerative disease in the adult, which is characterized by the pathological degeneration of condylar cartilage. Axin1 plays a critical r Show more
Osteoarthritis (OA) in the temporomandibular joint (TMJ) is a degenerative disease in the adult, which is characterized by the pathological degeneration of condylar cartilage. Axin1 plays a critical role in the regulation of cartilage development and homeostasis. To determine the role of Axin1 in TMJ tissue at the adult stage, we generated Axin1 Show less
📄 PDF DOI: 10.1002/jcp.27043
AXIN1
Meiyi Zhou, Jing Shao, Cheng-Yang Wu +17 more · 2019 · Diabetes · added 2026-04-24
Recent studies implicate a strong association between elevated plasma branched-chain amino acids (BCAAs) and insulin resistance (IR). However, a causal relationship and whether interrupted BCAA homeos Show more
Recent studies implicate a strong association between elevated plasma branched-chain amino acids (BCAAs) and insulin resistance (IR). However, a causal relationship and whether interrupted BCAA homeostasis can serve as a therapeutic target for diabetes remain to be established experimentally. In this study, unbiased integrative pathway analyses identified a unique genetic link between obesity-associated IR and BCAA catabolic gene expression at the pathway level in human and mouse populations. In genetically obese ( Show less
📄 PDF DOI: 10.2337/db18-0927
BCKDK
Shun Zhou, Guangpeng Jiang, Ying Zhu +5 more · 2019 · Fish & shellfish immunology · Elsevier · added 2026-04-24
Bactericidal permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP) play important roles in host antimicrobial defense. In the present study, we identified one isoform of B Show more
Bactericidal permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP) play important roles in host antimicrobial defense. In the present study, we identified one isoform of BPI/LBP gene from turbot (Scophthalmus maximus), designated as SmBPI/LBP1. The full-length cDNA sequence of SmBPI/LBP1 was 1826 bp, which encoding one secreted protein with 480 amino acid residues. Structurally, the SmBPI/LBP1 showed high similarity to its homologs from other vertebrates or invertebrates, which all contained a signal peptide, a BPI/LBP/CETP N-terminal with a LPS-binding domain, and a BPI/LBP/CETP C-terminal domain. The deduced amino acid sequences of SmBPI/LBP1 shared significant similarity to BPI/LBP of Seriola lalandi dorsalis (71%) and Paralichthys olivaceus (69%). Phylogentic analysis further supported that SmBPI/LBP1 act as a new member of vertebrate BPI/LBP family. SmBPI/LBP1 was ubiquitously expressed in all tested tissues, with the highest expression level in spleen tissue. The mRNA expression of SmBPI/LBP1 in spleen and kidney were significantly up-regulated after Vibrio vulnificus challenge. Finally, the recombinant SmBPI/LBP1 showed high affinity to lipopolysaccharide, followed by peptidoglycan and lipoteichoic acid, which is the ubiquitous component of Gram-negative or Gram-positive bacteria. These results indicated that SmBPI/LBP1 probably played important roles in immune response against bacteria infection. Show less
no PDF DOI: 10.1016/j.fsi.2019.02.004
CETP
Geting Wu, Yuanliang Yan, Yangying Zhou +7 more · 2019 · Current research in translational medicine · Elsevier · added 2026-04-24
Carbamoyl phosphate synthetase-1 (CPS1), the first rate-limiting mitochondrial enzyme in the urea cycle, regulates proliferation and differentiation during tumor progression. However, the detailed fun Show more
Carbamoyl phosphate synthetase-1 (CPS1), the first rate-limiting mitochondrial enzyme in the urea cycle, regulates proliferation and differentiation during tumor progression. However, the detailed function of CPS1 in glioblastoma Multiforme (GBM) is still unclear. Here, we highlight mechanisms for CPS1 upregulation and the effects of upregulated CPS1 on GBM tumorigenesis. The transcriptome data from several public databases, such as Oncomine and GEPIA, revealed that CPS1 transcriptional level was significantly upregulated in GBM tissues and cells. Moreover, CPS1 was hypomethylated in GBM tissues. The Wanderer database, linked to the Cancer Genome Atlas (TCGA), showed the association between CPS1 expression or its methylation values and the clinicopathological parameters in GBM patients. Our work fully demonstrated that CPS1 expression was upregulated in GBM and this gene could be used as a potential diagnostic and prognosis indicator for GBM. Show less
no PDF DOI: 10.1016/j.retram.2019.08.003
CPS1
Xu Liu, Mei Mei, Xiang Chen +8 more · 2019 · Respiratory research · BioMed Central · added 2026-04-24
Persistent pulmonary hypertension of the newborn (PPHN) is a severe clinical problem among neonatal intensive care unit (NICU) patients. The genetic pathogenesis of PPHN is unclear. Only a few genetic Show more
Persistent pulmonary hypertension of the newborn (PPHN) is a severe clinical problem among neonatal intensive care unit (NICU) patients. The genetic pathogenesis of PPHN is unclear. Only a few genetic polymorphisms have been identified in infants with PPHN. Our study aimed to investigate the potential genetic etiology of PPHN. This study recruited PPHN patients admitted to the NICU of the Children's Hospital of Fudan University from Jan 2016 to Dec 2017. Exome sequencing was performed for all patients. Variants in reported PPHN/pulmonary arterial hypertension (PAH)-related genes were assessed. Single nucleotide polymorphism (SNP) association and gene-level analyses were carried out in 74 PPHN cases and 115 non-PPHN controls with matched baseline characteristics. Among the patient cohort, 74 (64.3%) patients were late preterm and term infants (≥ 34 weeks gestation) and 41 (35.7%) were preterm infants (< 34 weeks gestation). Preterm infants with PPHN exhibited low birth weight and a high frequency of bronchopulmonary dysplasia, respiratory distress syndrome (RDS) and mortality. Nine patients (only one preterm infant) were identified as harboring genetic variants, including three with pathogenic/likely pathogenic variants in TBX4 and BMPR2 and six with variants of unknown significance in BMPR2, SMAD9, TGFB1, KCNA5 and TRPC6. Three SNPs (rs192759073, rs1047883 and rs2229589) in CPS1 and one SNP (rs1044008) in NOTCH3 were significantly associated with PPHN (p < 0.05). CPS1 and SMAD9 were identified as risk genes for PPHN (p < 0.05). In this study, we identified genetic variants in PPHN patients, and we reported CPS1, NOTCH3 and SMAD9 as risk genes for late preterm and term PPHN in a single-center Chinese cohort. Our findings provide additional genetic evidence of the pathogenesis of PPHN and new insight into potential strategies for disease treatment. Show less
📄 PDF DOI: 10.1186/s12931-019-1148-1
CPS1
Xiaobo Zhou, Yamin Rao, Qilin Sun +3 more · 2019 · Journal of cellular physiology · Wiley · added 2026-04-24
Long noncoding RNA CPS1-IT1 is recently recognized as a tumor suppressor in several cancers. Here, we investigate the role of CPS1-IT1 in human melanoma. Presently, our study reveals the low expressio Show more
Long noncoding RNA CPS1-IT1 is recently recognized as a tumor suppressor in several cancers. Here, we investigate the role of CPS1-IT1 in human melanoma. Presently, our study reveals the low expression of CPS1-IT1 in human melanoma tissues and cell lines, which is significantly associated with metastasis and tumor stage. Besides, the potential of CPS1-IT1 as a prognosis-predictor is strongly indicated. Functionally, CPS1-IT1 overexpression inhibits cell migration, invasion, epithelial-mesenchymal transition, and angiogenesis in melanoma cells. CYR61, an angiogenic factor that participates in tumor metastasis as well as a recognized oncogene in melanoma, is shown to be confined under CPS1-IT1 overexpression in melanoma cells. Furthermore, enforced expression of Cyr61 in CPS1-IT1-silenced melanoma cells dramatically normalized the protein level of Cyr61 and that of its downstream targets vascular endothelial growth factor and matrix metalloproteinase-9, as well as the repressive effect of CPS1-IT1 overexpression on melanoma cell metastasis. BRG1, a core component of SWI/SNF complex, is implied to interact with both CPS1-IT1 and Cyr61 in melanoma cells. Moreover, CPS1-IT1 negatively regulates Cyr61 expression by blocking the binding of BRG1 to Cyr61 promoter. Jointly, CPS1-IT1 controls melanoma metastasis through impairing Cyr61 expression via competitively binding with BRG1, uncovering a novel potential therapeutic and prognostic biomarker for patients with melanoma. Show less
no PDF DOI: 10.1002/jcp.28764
CPS1
Tianpeng Zhang, Min Chen, Lianxia Guo +4 more · 2019 · Hepatology (Baltimore, Md.) · Wiley · added 2026-04-24
Metabolic homeostasis of amino acids is essential for human health. Here, we aimed to investigate a potential role for the clock component reverse erythroblastosis virus α (Rev-erbα) in circadian regu Show more
Metabolic homeostasis of amino acids is essential for human health. Here, we aimed to investigate a potential role for the clock component reverse erythroblastosis virus α (Rev-erbα) in circadian regulation of amino acid metabolism. RNA-seq with Rev-erbα Show less
no PDF DOI: 10.1002/hep.30675
CPS1
Bo Zhang, Qiong Wu, Ran Xu +10 more · 2019 · Journal of cellular biochemistry · Wiley · added 2026-04-24
Overall survival of patients with low-grade glioma (LGG) has shown no significant improvement over the past 30 years, with survival averaging approximately 7 years. This study aimed to identify novel Show more
Overall survival of patients with low-grade glioma (LGG) has shown no significant improvement over the past 30 years, with survival averaging approximately 7 years. This study aimed to identify novel promising biomarkers of LGG and reveal its potential molecular mechanisms by integrated bioinformatics analysis. The microarray datasets of GSE68848 and GSE4290 were selected from GEO database for integrated analysis. In total, 293 overlapping differentially expressed genes (DEGs) were detected using the limma package. One hundred and eighty-eight nodes with 603 interactions were obtained from the establishment of protein-protein interaction (PPI) network. Functional and signaling pathway enriched were significantly correlated with the synapse and calcium signaling pathway, respectively. Module analysis revealed eight hub genes with high connectivity, which included CHRM1, DLG2, GABRD, GRIN1, HTR2A, KCNJ3, KCNJ9, and NUSAP1, and they were markedly correlated with patients' prognosis. The mining of the Gene Expression Profiling Interactive Analysis database and qPCR further confirmed the abnormal expression of these key genes with their prognostic value in LGG. We eventually predicted the 20 most vital small molecule drugs, which potentially reverse the carcinogenic state of LGG, as per the CMap (connectivity map) database and these DEGs, and MS-275 (enrichment score = -0.939) was considered as the most promising small molecule to treat LGG. In conclusion, our study provided eight reliable novel molecular biomarkers for diagnosis, prognosis prediction, and treatment targets for LGG. These conclusions will contribute to a better comprehension of molecular mechanisms fundamental to LGG occurrence and progression, and providing new insights for future development of genomic individualized treatment in LGG. Show less
no PDF DOI: 10.1002/jcb.28773
DLG2